share_log

JP Morgan Maintains Overweight on Prime Medicine, Lowers Price Target to $26

Benzinga ·  Nov 7, 2023 15:21

JP Morgan analyst Eric Joseph maintains Prime Medicine (NASDAQ:PRME) with a Overweight and lowers the price target from $27 to $26.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment